Plasma thioredoxin levels and platelet aggregability in patients with acute myocardial infarction

American Heart Journal

Volumn 146, Issue 3, 2003, Pages 465-471

  Miyamoto, Shinzo ^b   Sakamoto, Tomohiro ^b   Soejima, Hirofumi ^b   Shimomura, Hideki ^b   Kajiwara, Ichiro ^b   Kojima, Sunao ^b   Hokamaki, Jun ^b   Sugiyama, Seigo ^b   Yoshimura, Michihiro ^b   Ozaki, Yukio ^b   Nakamura, Hajime ^b   Yodoi, Junji ^b   Ogawa, Hisao ^a  

^a KUMAMOTO UNIV SCHOOL OF MEDICINE   (Japan)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

THIOREDOXIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTICLE; ATHEROSCLEROSIS; CONTROLLED STUDY; FEMALE; HEART LEFT VENTRICLE EJECTION FRACTION; HUMAN; LIGHT SCATTERING; MAJOR CLINICAL STUDY; MALE; OXIDATIVE STRESS; PRIORITY JOURNAL; STABLE ANGINA PECTORIS; THORAX PAIN; THROMBOCYTE AGGREGATION;

EID: 0042833235     PISSN: 00028703     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0002-8703(03)00311-9     Document Type: Article

References (41)

1. Berliner JA, Heinecke JW. The role of oxidized lipoproteins in atherogenesis. Free Radic Biol Med 1996;20:707-27.
2. Koster K, Hornykewycz S, Neunteufl YT, et al. Is oxidative stress causally linked to unstable angina pectoris? A study in 100 CAD patients and matched controls. Cardiovasc Res 1997;36:330-6.
3. Cipollone F, Ciabattoni G, Patrignani P, et al. Oxidative stress and aspirin-insensitive thromboxane biosynthesis in severe unstable angina. Circulation 2000;102:1007-13.
4. Teshigawara K, Maeda M, Nishino K, et al. Adult T leukemia cells produce a lymphokine that augments interleukin 2 receptor expression. J Mol Cell Immunol 1985;2:17-26.
5. Tagaya Y, Maeda Y, Mitsui A, et al. ATL-derived factor (ADF), an IL-2 receptor/Tac inducer homologous to thioredoxin: passible involvement of dithiol-reduction in the IL-2 receptor induction. EMBO J 1989;8:757-64.
6. Nakamura H, Nakamura K, Yodoi J. Redox regulation of cellular activation. Annu Rev Immunol 1997;15:351-69.
7. Nakamura H, De Rosa S, Roederer M, et al. Elevation of plasma thioredoxin levels in HIV-infected individuals. Int Immunol 1996;8:603-11.
8. Nakamura H, Vaage J, Valen G, et al. Measurements of plasma glutaredoxin and thioredoxin in healthy volunteers and during open-heart surgery. Free Radic Biol Med 1998;24:1176-86.
9. Fuster V, Badimon L, Badimon JJ, et al. The pathogenesis of coronary artery disease and acute coronary syndromes. N Engl J Med 1992;326:242-50.
10. Libby P. Molecular bases of acute coronary syndromes. Circulation 1995;91:2844-50.
11. Ruggeri ZM, Dent JA, Saldivar E. Contribution of distinct adhesive interactions to platelet aggregation in flowing blood. Blood 1999;94:172-8.
12. Goto S, Tamura N, Handa S, et al. Involvement of glycoprotein VI in platelet thrombus formation on both collagen and von Willebrand factor surfaces under flow conditions. Circulation 2002;106:266-72.
13. Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962;194:927-9.
14. Ries H, Braun G, Brehm G, et al. Critical evaluation of platelet aggregation in whole human blood. Am J Clin Pathol 1986;85:50-6.
15. Ozaki Y, Satoh K, Yatomi Y, et al. Detection of platelet aggregates with a particle counting method using light scattering. Anal Biochem 1994;218:284-94.
16. Satoh K, Ozaki Y, Qi R, et al. Factors that affect the size of platelet aggregates in epinephrine-induced activation: a study using the particle counting method based on light scattering. Thromb Res 1996;81:515-23.
17. Eto K, Takeshita S, Ochiai M, et al. Platelet aggregation in acute coronary syndromes: use of a new aggregometer with laser scattering to assess platelet aggregability. Cardiovas Res 1998;40:223-9.
18. Miyamoto S, Ogawa H, Soejima H, et al. Increased rate of formation of small-sized platelet aggregates in patients with acute coronary syndromes. Jpn Circ J 2000;64:647-52.
19. Ikeda H, Koga Y, Oda T, et al. Free oxygen radicals contribute to platelet aggregation and cyclic flow variations in stenosed and endothelium-injured canine coronary arteries. J Am Coll Cardiol 1994;24:1749-56.
20. Jourdan A, Aguejouf O, Imbault P, et al. Experimental thrombosis model induced by free radicals: application to aspirin and other different substances. Thromb Res 1995;79:109-23.
21. Yasue H, Horio Y, Nakamura N, et al. Induction of coronary artery spasm by acetylcholine in patients with variant angina: possible role of the parasympathetic nervous system in the pathogenesis of coronary artery spasm. Circulation 1986;74:955-63.
22. Tofler GH, Brezinski D, Schafer AI, et al. Concurrent morning increase in platelet aggregability and the risk of myocardial infarction and sudden cardiac death. N Engl J Med 1987;316:1514-8.
23. Sakamoto T, Ogawa H, Kawano H, et al. Rapid change of platelet aggregability in acute hyperglycemia detection by a novel laser-light scattering method. Thromb Haemost 2000;83:475-9.
24. Miyamoto S, Ogawa H, Soejima H, et al. Formation of platelet aggregates after attacks with coronary spastic angina pectoris. Am J Cardiol 2000;85:494-7.
25. Tohgi H, Takahashi H, Watanabe K, et al. Development of large platelet aggregates from small aggregates as determined by laser-light scattering: effect of aggregant concentration and antiplatelet medication. Thromb Haemost 1996;75:838-43.
26. Takemoto M, Liao JK. Pleiotropic effects of 3-hydroxy-3-methylglutary coenzyme A reductase inhibitors. Arterioscler Thromb Vasc Biol 2001;21:1712-9.
27. Salonen R, Nyssonen K, Porkkala-Saratahho, et al. The Kuopio Atherosclerosis Prevention Study (KAPS): effect of pravastatin treatment on lipids, oxidative resistance of lipoproteins, and atherosclerotic progression. Am J Cardiol 1995;76:34-9C.
28. Chirkov YY, Naujalis JI, Sage RE, et al. Antiplatelet effects of nitroglycerine in healthy subjects and in patients with stable angina pectoris. J Cardiovasc Pharmacol 1993;21:384-9.
29. Islim IF, Bareford D, Beevers DG. A single (investigator)-blind randomised control trial comparing the effect of quinapril and nifedipine on platelet function in patients with mild to moderate hypertension. Platelets 2001;12:274-8.
30. Mehta J, Li DY, Mehta JL. Vitamin C and E prolong time to arterial thrombosis in rats. J Nurr 1999;129:109-12.
31. Griffith TM, Edwards DH, Lewis MJ, et al. The nature of endothelium-derived relaxant factors. Nature 1984;308:645-7.
32. Rubanyi GM, Vanhoutte PM. Superoxide anions and hyperoxia inactivate endothelium-derived relaxing factors. Am J Physiol 1986;250:H822-7.
33. Azuma H, Ishikawa M, Sekizaki S. Endothelium-dependent inhibition of platelet aggregation. Br J Pharmacol 1986;88:411-5.
34. Davi G, Ciabattoni G, Consoli A, et al. In vivo formation of 8-isoprostaglandin F2α and platelet activation in diabetes mellitus: effects of improved metabolic control and vitamin E supplementation. Circulation 1999;99:224-9.
35. Abdiu A, Nakamura H, Sahaf B, et al. Thioredoxin blood levels increases after severe burn injury. Antioxid Redox Signal 2000;2:707-16.
36. Nakamura H, Matsuda M, Furuke K, et al. Adult T cell leukemia-derived factor/human thioredoxin protects endothelial F-2 cell injury caused by activated neutrophils or hydrogen peroxide. Immunol Lett 1994;42:75-80.
37. Xie L, Chesterman CN, Hogg PJ. Reduction of von Willebrand factor by endothelial cells. Thromb Haemost 2000;84:506-13.
38. Kishimoto C, Shioji K, Nakamura H, et al. Serum thioredoxin levels in patients with heart failure. Jpn Circ J 2001;65:491-4.
39. Belch JJ, Bridges AB, Scott N, et al. Oxygen free radicals and congestive heart failure. Br Heart J 1991;65:245-8.
40. Diaz-Velez CR, Garcia-Castineiras S, Mendoza-Ramos E, et al. Increased malondialdehyde in peripheral blood of patients with congestive heart failure. Am Heart J 1996;131:146-52.
41. Stephens NG, Parsons A, Schofield PM, et al. Randomized controlled trial of vitamin E in patients with coronary disease: Cambridge Heart Antioxidant Study (CHAOS). Lancet 1996;347:781-6.